Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study

<div><p>The ACCESS-model offers integrated care including assertive community treatment to patients with psychotic disorders. ACCESS proved more effective compared to standard care (ACCESS-I study) and was successfully implemented into clinical routine (ACCESS-II study). In this article, we report the 4-year outcomes of the ACCESS-II study. Between May 2007 and December 2013, 115 patients received continuous ACCESS-care. We hypothesized that the low 2-year disengagement and hospitalization rates and significant improvements in psychopathology, functioning, and quality of life could be sustained over 4 years. Over 4 years, only 10 patients disengaged from ACCESS. Another 23 left for practical reasons and were successfully transferred to other services. Hospitalization rates remained low (13.0% in year 3; 9.1% in year 4). Involuntary admissions decreased from 35% in the 2 years prior to ACCESS to 8% over 4 years in ACCESS. Outpatient contacts remained stably high at 2.0–2.4 per week. We detected significant improvements in psychopathology (effect size <i>d = 0.79</i>), illness severity (<i>d = 1.29</i>), level of functioning (<i>d = 0.77</i>), quality of life (<i>d = 0.47</i>) and stably high client satisfaction (<i>d = 0.02</i>) over 4 years. Most positive effects were observed within the first 2 years with the exception of illness severity, which further improved from year 2 to 4. Within continuous intensive 4-year ACCESS-care, sustained improvements in psychopathology, functioning, quality of life, low service disengagement and re-hospitalization rates, as well as low rates of involuntary treatment, were observed in contrast to other studies, which reported a decline in these parameters once a specific treatment model was stopped. Yet, stronger evidence to prove these results is required.</p><p><b>Trial registration:</b> Clinical Trial Registration Number: <a href="https://clinicaltrials.gov/ct2/show/NCT01888627" target="_blank">NCT01888627</a></p></div

Course of illness of all patients (N = 115).

<p>Course of illness of all patients (N = 115).</p

Baseline variables.

<p>Baseline variables.</p

Characteristics of the ACCESS treatment and inclusion/exclusion criteria.

<p>Characteristics of the ACCESS treatment and inclusion/exclusion criteria.</p

Sample flow chart.

<p>Patients of the study were recruited from 1st of May 2007 to 31st of October 2009. 115 patients with SSD or BD and severe mental illness were included for the study. All treated patients (N = 115) participated in the assessments, which were administered as part of the clinical routine.</p